Alzbeta Dlabkova

Alzbeta Dlabkova

Auto-generated profile, based on publicly available information

Alzbeta Dlabkova

University of Defence, Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, Hradec Králové, Czech Republic

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
MHMartina Hrabinova
Martina Hrabinova
JPJaroslav Pejchal
Jaroslav Pejchal
VHVendula Hepnarova
Vendula Hepnarova
LMLubica Muckova
Lubica Muckova
LJLucie Junova
Lucie Junova
DJDaniel Jun
Daniel Jun
A-series agent A-234 belongs to a new generation of nerve agents. The poisoning of a former Russian spy Sergei Skripal and his daughter in Salisbury, England, in March 2018 led to the inclusion of A-234 and other A-series agents into the Chemical Weapons Convention. Even though five years have already passed, there is still very little information on its chemical properties, biological activities, and treatment options with established antidotes. In this article, we first assessed A-234 stability in neutral pH for subsequent experiments. Then, we determined its inhibitory potential towards human recombinant acetylcholinesterase (HssAChE; EC 3.1.1.7) and butyrylcholinesterase (HssBChE; EC 3.1.1.8), the ability of HI-6, obidoxime, pralidoxime, methoxime, and trimedoxime to reactivate inhibited cholinesterases (ChEs), its toxicity in rats and therapeutic effects of different antidotal approaches. Finally, we utilized molecular dynamics to explain our findings. The results of spontaneous A-234 hydrolysis showed a slow process with a reaction rate displaying a triphasic course during the first 72 h (the residual concentration 86.2%). A-234 was found to be a potent inhibitor of both human ChEs (HssAChE IC50 = 0.101 ± 0.003 µM and HssBChE IC50 = 0.036 ± 0.002 µM), whereas the five marketed oximes have negligible reactivation ability toward A-234-inhibited HssAChE and HssBChE. The acute toxicity of A-234 is comparable to that of VX and in the context of therapy, atropine and diazepam effectively mitigate A-234 lethality. Even though oxime administration may induce minor improvements, selected oximes (HI-6 and methoxime) do not reactivate ChEs in vivo. Molecular dynamics implies that all marketed oximes are weak nucleophiles, which may explain the failure to reactivate the A-234 phosphorus-serine oxygen bond characterized by low partial charge, in particular, HI-6 and trimedoxime oxime oxygen may not be able to effectively approach the A-234 phosphorus, while pralidoxime displayed low interaction energy. This study is the first to provide essential experimental preclinical data on the A-234 compound.

21 August 2018 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
NVNela Vanova
Nela Vanova
LMLubica Muckova
Lubica Muckova
MSMonika Schmidt
Monika Schmidt
DHDavid Herman
David Herman
ADAlzbeta Dlabkova
Alzbeta Dlabkova
DJDaniel Jun
Daniel Jun

30 November 2019 in Drug Testing and Analysis
Verified
Journal Article
Closed access
PDF file
DHDavid Herman
David Herman
ADAlzbeta Dlabkova
Alzbeta Dlabkova
LCLenka Cechova
Lenka Cechova
NVNela Vanova
Nela Vanova
JMJan Misik
Jan Misik
JKJana Zdarova Karasova
Jana Zdarova Karasova

9 January 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MVMartin Valis
Martin Valis
ADAlzbeta Dlabkova
Alzbeta Dlabkova
JHJakub Hort
Jakub Hort
FAFrancesco Angelucci
Francesco Angelucci
JPJaroslav Pejchal
Jaroslav Pejchal
MNMichal Novotný
Michal Novotný
The acetylcholinesterase inhibitor donepezil is administered as a treatment for Alzheimer's disease (AD). However, the appropriate donepezil dosage is still a matter of debate. Forty AD patients receiving 10 mg/day of donepezil were randomly divided into four groups based on the time of plasma and cerebrospinal fluid (CSF) sampling: 6 h (n = 5), 12 h (n = 12), 18 h (n = 6) and 24 h (n = 17) after donepezil administration. High-performance liquid chromatography measured the donepezil concentration in plasma samples and CSF samples collected at 4-time points. Plasma and CSF levels among the groups were not significantly different. Conversely, the CSF/plasma donepezil concentration ratio considerably increased in the 24 h group compared to the 6 h (p < 0.005) and 12 h (p < 0.05) groups. The measurement of the CSF/plasma donepezil concentration ratio could be used to better evaluate the optimal dose of donepezil.

24 May 2024 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
EPEliska Prchalova
Eliska Prchalova
RARudolf Andrys
Rudolf Andrys
JPJaroslav Pejchal
Jaroslav Pejchal
ZKZuzana Kohoutova
Zuzana Kohoutova
KKKarolina Knittelova
Karolina Knittelova
DMDávid Maliňák
Dávid Maliňák

19 June 2021 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
ADAlzbeta Dlabkova
Alzbeta Dlabkova
DHDavid Herman
David Herman
LCLenka Cechova
Lenka Cechova
MHMilos Hroch
Milos Hroch
NVNela Vanova
Nela Vanova
JKJana Zdarova Karasova
Jana Zdarova Karasova